Abstract
Hepatitis C virus (HCV) infection is present in 1.8% of the general US population and its prevalence worldwide is estimated at 2–3%. HCV infected patients with concomitant rheumatoid arthritis (RA) pose a particular challenge to the rheumatologist because of the risks of treatment with disease-modifying medications in patients with chronic liver infection. In this paper the difficulties of diagnosing RA in HCV patients and the safety of RA treatment in patients with both conditions are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 35-40 |
| Number of pages | 6 |
| Journal | Therapeutic Advances in Musculoskeletal Disease |
| Volume | 4 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2012 |
Keywords
- biological-response modifiers
- disease-modifying antirheumatic drugs
- hepatitis C
- rheumatoid arthritis
Fingerprint
Dive into the research topics of 'Treatment of rheumatoid arthritis in patients with concomitant chronic hepatitis C infection'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver